Top Markets
Coin of the day
InDex Pharmaceuticals Holding AB (publ) InDex Pharmaceuticals Holding AB (publ)

InDex Pharmaceuticals Holding AB (publ)

INDEX
Rank in Stocks #28996
InDex Pharmaceuticals Holding AB (publ) is a pharmaceutical firm dedicated to... InDex Pharmaceuticals Holding AB (publ) is a pharmaceutical firm dedicated to developing therapeutic solutions for patients affected by ulcerative colitis. The company's flagship drug candidate, Cobitolimod, is presently in Phase III clinical trials, targeting the treatment of moderate to severe ulcerative colitis. Furthermore, InDex is progressing a pipeline of other DNA-based immunomodulatory sequences, which are in the preclinical phase, designed to address various immunological conditions. This enterprise was established in 2000 and operates from its headquarters in Solna, Sweden.
Share Price
$0.04406501
Last synced: 2024-07-09
Market Cap
$23.47M
Change (1 day)
-0.48%
Change (1 year)
0.00%
Country
SE
Trade InDex Pharmaceuticals Holding AB (publ) (INDEX)

Category

Operating Margin for InDex Pharmaceuticals Holding AB (publ) (INDEX)
Operating Margin as of 2026 TTM: 0.00%
According to InDex Pharmaceuticals Holding AB (publ) latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for InDex Pharmaceuticals Holding AB (publ) from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.59% -
US
-149.01% -
US
28.81% -
NL
25.72% -
AU
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.